Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

ACR Leaders Discuss Hydroxychloroquine Issues with FDA Commissioner

From the College  |  August 10, 2020

Since hydroxychloroquine (HCQ) was mentioned as a possible treatment for COVID-19, ACR members have expressed concern and frustration about their patients’ access to this critical treatment. Specifically, members and patients have experienced issues with prescription restrictions, prior authorization requirements and patient concerns about cardiac side effects. The ACR has been in constant communication with the U.S. Food & Drug Administration (FDA) and private insurers to address these issues and has released guidance documents to assist members during this public health emergency (PHE), including the following:

  • ACR Guiding Principles for Hydroxychloroquine Scarce Resource Allocation During the COVID-19 Pandemic
  • Advice for Talking to Patients About Shortages of Hydroxychloroquine During the COVID-19 Pandemic

In response to its constant communication with the FDA, the ACR and its leadership had the opportunity to speak with FDA Commissioner Stephen Hahn, MD, to discuss provider experiences with HCQ during the PHE. Members of the ACR’s leadership discussed difficulties in obtaining HCQ for patients at the onset of the PHE as well as subsequent concerns about cardiac concerns related to HCQ. The FDA noted that it is working with manufacturers to ensure adequate supply for patients. Agency staff expressed interest in working with the ACR as they continue to discuss tools and guidance on concerns about cardiac side effects of HCQ.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

ACR staff will continue to work with the FDA and private insurance companies to ensure that rheumatology patients can access HCQ. The ACR’s Insurance Subcommittee (ISC) of the Committee on Rheumatologic Care is ready and willing to help members who are experiencing access or administrative burden issues related to HCQ. The ISC’s recent advocacy on this issue has led to changes in payer prior authorization processes, making it easier for rheumatology patients to access this critical medication. For questions or assistance with a specific payer policy, contact [email protected].

Access resources can be found on the ACR website.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Share: 

Filed under:InsuranceLegislation & AdvocacyPractice Support Tagged with:Access to medicationACR Insurance Subcommittee (ISC)COVID-19Hydroxychloroquine (HCQ)U.S. Food and Drug Administration (FDA)

Related Articles

    Reading Rheum

    November 1, 2007

    Handpicked Reviews of Contemporary Literature

    Should Hydroxychloroquine Level Testing Be Standard Care in Lupus?

    February 13, 2020

    The Johns Hopkins Lupus Center, Baltimore, has described its experience using hydroxychloroquine (HCQ) levels.1 Forty-four percent of its patients had levels below 500 ng/mL (partial nonadherence); 13% were severely nonadherent (<200 ng/mL). They were shown their results and educated on HCQ adherence. Adherence then improved to 80%; those with lower HCQ levels had higher disease…

    Rheumatologists Debate Hydroxychloroquine Dosing Guidelines for Lupus

    February 18, 2019

    CHICAGO—The correct dosing of hydroxychloroquine (HCQ) for systemic lupus erythematosus (SLE) is a concern of all rheumatologists. Petros Efthimiou, MD, clinical professor of medicine at New York University, New York City, opened the Great Debate of the 2018 ACR/ARHP Annual Meeting by stating, “Today, we will be discussing a critical clinical problem that affects everyone’s…

    New Study Probes Hydroxychloroquine Adherence During Pregnancy

    May 11, 2023

    Hydroxychloroquine (HCQ) is nearly universally recommended for pregnant patients with systemic lupus erythematosus (SLE) to reduce lupus disease activity and adverse outcomes in pregnancy.1-3 Yet despite strong evidence supporting its benefits, HCQ appears underutilized, with several studies suggesting fewer than half of all women with lupus take this medication during pregnancy.4 How accurately these results…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences